AKI is characterized by a rapid decline in kidney function and carries high rates of illness and death. Despite its severity, no specific therapy has been approved for this condition. The kidneys are among the most metabolically active organs in the body. When AKI occurs, the metabolic network within kidney cells undergoes profound disruption, leading to energy depletion, mitochondrial damage, oxidative stress, and inflammation. As a result, strategies that target cellular energy metabolism have emerged as a promising direction for AKI treatment.
NAD + plays a central role in cellular energy metabolism, supporting ATP synthesis, mitochondrial function, and antioxidant defense. In AKI, however, NAD+ levels in kidney cells drop significantly, making NAD + replenishment an attractive therapeutic strategy. Current approaches mainly rely on NAD + precursors such as nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide (Nam). But even at high doses, these precursors show limited efficacy—they are rapidly metabolized in the body, and the key enzymes that drive these pathways are often downregulated during AKI, further restricting their effectiveness.
In fact, the body’s primary route for maintaining kidney NAD + levels is the de novo biosynthesis pathway. Recent studies have found that during AKI, the key enzyme in this pathway, QPRT, is significantly reduced, while NAD + -consuming enzymes are abnormally increased. This two‑sided imbalance severely disrupts NAD + homeostasis. Even if NAD + levels are restored, proper cellular energy function also requires electrons—yet in AKI, kidney cells are starved of high‑energy electrons because fatty acid oxidation, the main source of these electrons, is also impaired. Simply increasing NAD + supply, therefore, is unlikely to fully repair cellular energy metabolism.
A research team recently discovered that microglial cells show a marked increase in QPRT expression when exposed to hydrogen peroxide (H₂O₂). Building on this finding, the team loaded olaparib—an inhibitor of the NAD + -consuming enzyme PARP—into nanovesicles derived from H₂O₂‑treated microglial cells. This created a novel nano-delivery system called CNV@Ola. After administration, the nanoscale vesicles take advantage of the increased permeability of the kidney’s filtration barrier during AKI, accumulating efficiently in damaged kidney tissue and entering renal cells. Once inside, CNV@Ola works through two complementary mechanisms: it boosts NAD + synthesis via QPRT catalysis and simultaneously reduces NAD + consumption by delivering olaparib. This dual action rapidly restores NAD + levels and, through the NAD + /SIRT/PGC-1α signaling pathway, repairs damaged mitochondria and significantly enhances fatty acid oxidation. The result is a marked increase in NADH production, rapid recovery of ATP synthesis, and efficient clearance of reactive oxygen species.
The approach not only halted disease progression in clinically relevant AKI models but also prevented the transition from AKI to chronic kidney disease (CKD). Importantly, the strategy protected against high‑dose cisplatin‑induced kidney damage without compromising the chemotherapy’s anticancer efficacy—highlighting its strong potential for clinical translation. Because this biomimetic strategy uses naturally derived nanovesicles, it achieves NAD + -mediated metabolic reprogramming without the need for complex chemical synthesis or genetic engineering. This offers a novel and promising drug development platform not only for AKI but also for other diseases characterized by disrupted energy metabolism.
Science Bulletin
Experimental study